Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema--a comparative pilot study

• Published in: BMC ophthalmology Vol. 11; no. 1; p. 36
• Main Authors: Norlaili, Mustapha, Bakiah, Shaharuddin, Zunaina, Embong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 23.11.2011; BioMed Central; BMC
• Subjects: Acuity; Adult; Aged; Anti-Inflammatory Agents - administration & dosage; Astigmatism; Automation; Blindness; Breakdowns; Diabetes; Diabetes mellitus; Diabetic retinopathy; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - surgery; Diagnosis; Dropsy; Drug therapy; Edema; Female; Health aspects; Humans; Intravitreal Injections; Laser Coagulation; Lasers; Macular Edema - drug therapy; Macular Edema - surgery; Male; Middle Aged; Ophthalmology; Patients; Permeability; Pilot Projects; Retina; Sample size; Severity of Illness Index; Statistical analysis; Tomography; Triamcinolone; Triamcinolone - administration & dosage; Triamcinolone acetonide; Visual Acuity; Visual perception; Malaysia
• ISSN: 1471-2415; 1471-2415
• DOI: 10.1186/1471-2415-11-36

Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk of visual loss. However recurrences are common and despite laser treatment, patients with diabetic macular oedema experienced progressive loss of vision. Stabilization of the blood retinal barrier introduces a rationale for intravitreal triamcinolone treatment in diabetic macular oedema. This study is intended to compare the best corrected visual acuity (BCVA) and the macular oedema index (MEI) at 3 month of primary treatment for diabetic macular oedema between intravitreal triamcinolone acetonide (IVTA) and laser photocoagulation. This comparative pilot study consists of 40 diabetic patients with diabetic macular oedema. The patients were randomized into two groups using envelope technique sampling procedure. Treatment for diabetic macular oedema was based on the printed envelope technique selected for every patient. Twenty patients were assigned for IVTA group (one injection of IVTA) and another 20 patients for LASER group (one laser session). Main outcome measures were mean BCVA and mean MEI at three months post treatment. The MEI was quantified using Heidelberg Retinal Tomography II. The mean difference for BCVA at baseline [IVTA: 0.935 (0.223), LASER: 0.795 (0.315)] and at three months post treatment [IVTA: 0.405 (0.224), LASER: 0.525 (0.289)] between IVTA and LASER group was not statistically significant (p = 0.113 and p = 0.151 respectively). The mean difference for MEI at baseline [IVTA: 2.539 (0.914), LASER: 2.139 (0.577)] and at three months post treatment [IVTA: 1.753 (0.614), LASER: 1.711 (0.472)] between IVTA and LASER group was also not statistically significant (p = 0.106 and p = 0.811 respectively). IVTA demonstrates good outcome comparable to laser photocoagulation as a primary treatment for diabetic macular oedema at three months post treatment. ISRCTN05040192 (http://www.controlled-trial.com).